NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO
Today,
If all warrants of series TO3 are exercised, the Company will receive approximately
Summarized terms for the warrants of series TO3:
Exercise period:
Issue volume: 46,739,208 warrants of series TO3 entitle the subscription of 46,739,208 series B shares. At full exercise, the Company receives approximately
Subscription price:
Last day of trading with warrants of series TO3:
Share capital and dilution: At full exercise of the warrants of series TO3, the share capital increases by
Please be advised: The invested amount must be rounded up to two decimal places.
Please note that the warrants not exercised by
How the warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrant shall be made in accordance with instructions from the respective nominee. Please contact your nominee for further information.
Direct-registered Warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration by the Swedish Companies Registration Office.
Advisors
For more information contact:
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog's products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by
Further information regarding the company is available at https://pharmacolog.com/.
The company's Certified Adviser is
Important information
The publication, announcement, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions under law, and individuals in jurisdictions where this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from any other party.
This press release does not constitute an offer to sell or an invitation to acquire or subscribe for securities in
https://news.cision.com/pharmacolog/r/the-last-day-of-trading-with-warrants-of-series-to3-in-pharmacolog-is-today--february-20--2024,c3931757
https://mb.cision.com/Main/12317/3931757/2614628.pdf
https://news.cision.com/pharmacolog/i/pharmacolog-news-500x388px-100,c3269245
(c) 2024 Cision. All rights reserved., source